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See Article, pages 958–968Surgical resection is an accepted treatment for hepa-
tocellular carcinoma (HCC) [1]. However, its applicabil-
ity is limited by several factors. In the large majority of
cases, HCC develops in the context of underlying liver
disease, usually in association with cirrhosis. Signiﬁcant
hepatic dysfunction or the presence of clinically relevant
portal hypertension has a profound impact on the out-
comes after resection. Consequently, the majority of
patients with HCC will not be reasonable candidates
for resection due to advanced liver disease. In addition,
multifocality of the tumor as a result of intrahepatic
metastases via microscopic invasion of the portal system
often precludes curative resection and is also considered
by many centers to be a contraindication to surgical
resection. Well selected patients undergoing resection
of HCC at an experienced center would be expected to
have good outcomes with perioperative mortality below
3%, blood transfusion in less than 10% of cases, and
5-year survival rates of at least 50% [2]. Unfortunately,
even in well selected patients, resection is plagued by
recurrence rates of approximately 70% at 5 years as a
result of occult metastases that were not detected at
the time of resection as well as the formation of de novo
tumors in the remaining cirrhotic liver [2]. Studies have0168-8278/$36.00  2009 European Association for the Study of the Liver.
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vascular invasion, tumor size, presence of satellites,
degree of diﬀerentiation, as well as alphafetoprotein
(AFP) levels. Several strategies to prevent and treat recur-
rence have been evaluated over the years (Table 1) [3–18].
Although some of them have shown promising initial
results, most of these studies have lacked proper study
design or an adequate sample size. In addition, even
the treatments with positive results have not been
adopted in routine clinical practice, not even at the cen-
ters that reported the trials. Therefore, clinical trials
assessing adjuvant therapies after resection are urgently
needed [19].
In this issue of the Journal, we focus our attention on
a randomized, multicenter, phase II study by Liu et al.
that evaluates the heparanase inhibitor PI-88 as an adju-
vant therapy for HCC after curative resection [14].
Patients with a histological diagnosis of HCC undergo-
ing hepatectomy conﬁrmed as curative by a postopera-
tive CT scan were included and randomized to three
arms: untreated control group (group A) and two treat-
ment groups: 160 mg PI-88/day (group B) and 250 mg
PI-88/day (group C). The primary endpoints were
non-recurrence rate and safety and the secondary end-
point was the time to recurrence in the intention-to-treat
population. The main result of this study was that after
48 weeks of follow-up, 29 patients (50%) in group A, 35
(63%) in group B and 22 (41%) in group C remained
recurrence-free at completion. These diﬀerences did
not reach statistical signiﬁcance but met the criteria to
proceed with further investigation of PI-88 at thePublished by Elsevier B.V. All rights reserved.
Table 1
Studies of neo-adjuvant and adjuvant therapies for resection of HCC.
Study n Intervention Outcome
Treatment of micrometastases
Izumi [3] 50 Postop lipiodol No diﬀerence with control
Wu [4] 52 Preop chemoembolization No diﬀerence with control
Li [5] 94 Postop lipiodol No diﬀerence with control
Yamasaki [6] 97 Preop chemoembolization No diﬀerence with control
Yamamoto [7] 67 Postop 5FU No diﬀerence with control
Khono [8] 88 Postop lipiodol No diﬀerence with control
Ono [9] 108 Postop epirubicin + carmofur No diﬀerence with control
Lai [10] 66 Postop lipiodol No diﬀerence with control
Ueno [11] 21 Postop lipiodol No diﬀerence with control
Takayama [12] 150 Adoptive immunotherapy Signiﬁcant decrease in recurrence
Lau [13] 43 Postop I-131 lipiodol Signiﬁcant decrease in recurrence
Liu [14] 168 Postop PI-88 No diﬀerence with control but evidence for further study
Chemoprevention of de novo HCC
Muto [15] 89 Polyprenoic acid Signiﬁcant decrease in recurrence
Ikeda [16] 20 Interferon Signiﬁcant decrease in recurrence
Mazzaferro [17] 150 Interferon Signiﬁcant decrease in late recurrence
Lo [18] 80 Interferon Signiﬁcant decrease in recurrence
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associated with PI-88 were cytopenia, injection site hem-
orrhage, PT prolongation, and hepatotoxicity-related
withdrawals, particularly in patients receiving the higher
dose of PI-88. The authors’ main conclusions were that
PI-88 at 160 mg/day was optimal and safe, and showed
preliminary eﬃcacy as an adjuvant therapy for HCC
after resection. A more comprehensive trial of PI-88 at
160 mg/day in this clinical setting was suggested.
The design of clinical trials in HCC is a complex
issue: inclusion criteria are frequently heterogeneous,
diagnostic criteria are not always standardized, and
stratiﬁcation by well-known prognostic factors is usually
omitted. These concerns have made it diﬃcult to com-
pare, analyze and interpret results of reported studies.
Furthermore, the selection of appropriate primary and
secondary endpoints is crucial for capturing beneﬁts in
outcomes that might be achieved with these new inter-
ventions. As a consequence, only a few medical interven-
tions have been rigorously tested in the treatment of
HCC. In fact, a study reviewing randomized trials in
HCC found that two-thirds of these studies had less
than optimal study designs and methodology [20].
The current study published by Liu and coworkers
adds yet a new piece to the puzzle of HCC treatment
and opens the door for evaluating the heparanase inhib-
itor PI-88 in a larger, phase III trial. The authors should
be congratulated for their selection of a randomized
phase II trial projected according to the Simon’s 2-stage
optimal design [21] for testing a new drug since this type
of study minimizes the likelihood of erroneous conclu-
sions regarding eﬃcacy. The execution of a single arm,
non-randomized phase 2 study would probably have
lead to a negative study and, perhaps, would have cur-
tailed the evaluation of a promising drug.Some may argue that ideally, only compounds found
to have eﬀect in trials on patients with advanced HCC
should be used in an adjuvant setting. However, one
must keep in mind the mechanism of action of the drug
being studied. PI-88 is proposed to block the ability of
the cancer to degrade heparan sulfate in the extracellular
matrix and thus prevent the tumor from developing
metastases. Thus, it may be possible for PI-88 or other
drugs to be an eﬀective adjuvant therapy without having
signiﬁcant impact on advanced cases of HCC.
However, the readers should keep in mind several
issues when examining this study. First, the inclusion
criteria called for all patients with a histological diagno-
sis of HCC undergoing curative hepatectomy as con-
ﬁrmed by a postoperative CT scan. There were no
inclusion or exclusion criteria based on tumor stage.
As a result, a patient’s suitability for resection was deter-
mined by each individual center. As long as the patients
had a postoperative CT scan demonstrating no residual
HCC, they could be enrolled into the study. Conse-
quently, the study population was quite heterogeneous
with a large proportion of the patients having advanced
HCC (micro or macrovascular invasion in 39/168 cases,
multinodular or massive HCC in 38/168 patients). It is
critical to select a homogeneous patient population for
the evaluation of new agents. Otherwise, the results of
clinical trials will be diﬃcult to interpret since diﬀerences
in outcome due to the intervention can be lost due to
vast diﬀerences in the expected natural outcomes of
patients. Random eﬀect from the inclusion of such a het-
erogeneous patient population may explain why PI-88 at
the higher dose was not found to be eﬀective. Trials
assessing the eﬃcacy of new drugs being used as adju-
vant therapy after radical treatment should ideally
include patients with early HCC. Well-deﬁned and
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vided, avoiding decisions by individual centers that
can only lead to selection biases. The Barcelona Clinic
Liver Cancer (BCLC) prognosis system [22] has emerged
during recent years as the standard classiﬁcation that is
used for trial design and clinical management of patients
with HCC [1,19], and in this setting, the inclusion of
BCLC stage 0-A patients will help to select a homoge-
neous patient population. Furthermore, in studies that
have tissue specimens available, patients should be strat-
iﬁed for high or low risk of recurrence prior to random-
ization. Patient stratiﬁcation should ideally be
performed based on well-established predictors of
recurrence such as the presence of vascular invasion,
satellite nodules, tumor multinodularity, and poor
diﬀerentiation.
Another key point in the design of phase II trials in
HCC is the selection of appropriate primary and sec-
ondary endpoints. Proper selection of these endpoints
is critical for capturing potential beneﬁts of the new
interventions. This statement is particularly true with
the advent of targeted agents, which usually have a
cytostatic eﬀect by arresting tumor growth. These
types of agents may have beneﬁt in terms of survival
with no measurable response rate. Thus, for these type
of therapies, a time-to-event endpoint may be better
able to detect a beneﬁt. In the current study, the
authors have chosen non-recurrence at 48-week of fol-
low-up as the primary endpoint which may be insuﬃ-
cient to detect a potential beneﬁt. Some drugs may act
vigorously in delaying but not avoiding the appearance
of recurrences, thus translating into a signiﬁcant
improvement in survival without actually reducing
the recurrence rate. Under the current study design,
the beneﬁt of such agents may be disregarded and their
evaluation could be prematurely terminated because of
an apparent lack of eﬃcacy. We are convinced that the
best primary endpoint in this study would have been
time to recurrence.
Nevertheless, we should not lose sight of the accom-
plishment of the authors. Randomized and controlled
trials in the ﬁeld of HCC are diﬃcult to conduct and
thus sorely lacking and desperately needed. The authors
should be commended for having conducted a study
that fulﬁlls the criteria put forward by the CONSORT
statement [23]. In addition they have chosen to evaluate
their agent with a randomized phase II trial before pro-
ceeding with a large and expensive phase III trial.
Unfortunately, their selection of a suboptimal endpoint
and inclusion of a heterogenous population makes it dif-
ﬁcult to come to robust conclusions. Based on the
authors ﬁndings, PI-88 was moved forward to a Phase
III trial which has, unfortunately, closed early and prior
to completion.
The success of sorafenib in the treatment of advanced
HCC has opened the door for the use of such small tar-geted molecules in the adjuvant setting [24]. As more
and more of such small molecular therapies are devel-
oped, there will be a growing need for studies to evaluate
their eﬃcacy in the treatment of HCC. It will be more
important than ever to conduct well-designed trials with
properly selected patients and endpoints, not only to
capture their potential beneﬁts but also to prevent waste
of limited resources.Acknowledgement
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